#rxf2018

Sold
out!

Research Xchange Forum 2018

Insights | Translation | Solutions
Trends and Challenges in Regenerative Medicine and Cell Therapy 

March 20-21, 2018
Sartorius College
Goettingen, Germany
Save to your calendar

Our Research Xchange Forum brings together experts from academia and industry to foster the exchange of ideas and to stimulate dialog about the next generation of interdisciplinary research. Join our discussions and listen to keynote lectures by leading international biopharma R&D experts. Further highlights: The winner and the finalists of "The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy 2018" will present the results of their research.

Who Should Attend

This forum is ideal for professionals of these areas:

  • Pharmaceutical and biopharmaceutical companies
  • Universities and research institutes
  • Contract services and research laboratories
  • Government testing agencies

6 Reasons Why You Need to Be a Part of This Xchange

1. Gain insights into the latest findings

  • Keynote lectures on cellular immunotherapy by R&D experts
  • Lectures from internationally renowned industry and academic speakers on the latest developments in Regenerative Medicine and Cell Therapy

2. Meet the winner and finalists of the "Sartorius & Science Prize"

  • Lectures to be held by the winner and the 3 finalists of “The Sartorius & Science Prize for Regenertaive Medicine & Cell Therapy
  • Speech by Science editor Dr. Priscilla N. Kelly  
  • Gala dinner and awards ceremony for exceptional scientists

3. Join our discussions and meet partners for potential collaboration

  • Panel discussion with stakeholders from industry and academia, including Science editor Dr. Priscilla N. Kelly  
  • Thought-provoking dialog and networking opportunities with like-minded companies and academic professionals to gain a better understanding of their workflows and challenges

4. Learn the secrets of winning a Nobel Prize

  • Prof. Dr. Stefan Hell will give an inspirational speech on how to win a Nobel Prize

5. Attend application sessions on our latest developments

  • Sessions on monitoring of T-cell activation, rapid bacteria detection, automated systems for scale-up of cell therapy products, and in vitro chemotaxis assays
  • Sartorius experts will explain product functionalities and give pointers on how to improve workflows

6. Gain exclusive insights into applications and manufacturing

  • A plant tour will provide useful insights into Sartorius manufacturing operations
  • A scale-up lab demonstration will show you how to scale up single-use bioreactors, prepare media, clarify cell cultures and perform aseptic processing

Agenda

Chair: Ruth McDermott

 

09:40Transfer to Sartorius College (from hotel)
10:00 – 11:00Registration
11:00 – 11:30Welcome & Introduction

Gerry MacKay, Sartorius, Germany

Member of the Group Executive Commitee and Executive Vice President LPS Marketing | Sales | Services

11:30 – 12:00Inspirational speech: How to win a Nobel Prize

Prof. Dr. Stefan Hell, Max Planck Institute for Biophysical Chemistry, Germany

Managing Director and Nobel Prize laureate of 2014 in chemistry

12:00 – 12:30How to publish in Science

Dr. Priscilla N. Kelly, AAAS | Science, USA

Editor

12:30 – 13:15Lunch break | Application Session
13:15 – 14:00Keynote presentationSartorius & Science Prize Winner
14:00 – 14:30LectureSartorius & Science Prize Finalist 1
14:30 – 15:00Coffee break
15:00 – 15:30LectureSartorius & Science Prize Finalist 2
15:30 – 16:00LectureSartorius & Science Prize Finalist 3
16:00 – 17:00

Panel Discussion

In search of excellence -Scientific publications in the 21st century

Moderation: Dr. Reinhard Baumfalk, Sartorius, Germany

Vice President R&D Instrumentation & Control


Participants: Prof. Dr. Stefan Hell, Dr. Priscilla N. Kelly, Dr. Ulf Geumann

17:00 – 17:15Sum up & Closing
17:20Transfer to hotel (from Sartorius College)
18:15Transfer to award ceremony (from hotel)
18:30 – 23:30Award ceremony
23:30Transfer to hotel

Chair: Del Trezise

 

08:15Transfer to Sartorius College | Sartorius Trainingscenter (from hotel)
08:30 – 10:00

Optional Plant Tour (Sartorius College)

or

Upscaling Lab Demonstration Tour (Sartorius Trainingscenter)

09:40Transfer to Sartorius College (from Sartorius Traningscenter)
10:00 – 10:15Opening Day 2
10:15 – 11:00Manufacturing strategies for patient scale cell therapies

Dr. Nina G. Bauer, Lonza, Switzerland

Assoc. Director of Commercial Development, Autologous Cell Therapies

11:00 – 11:30Allogenic approach development by Servier and the preclinical data of UCART19

Dr. Thierry Wurch, Servier, France

Director of External Studies in Immuno-oncology

11:30 – 12:30Lunch break | Application & Poster Session
12:30 – 13:00Small molecules to enable, faciliate and improve iPSC generation and cell reprogramming

Prof. Dr. Stefan Wölfl University Heidelberg, Germany

Institute for Pharmacy and molecular Biotechnology

13:00 – 13:30Mesenchymal stem cells in immunotherapy

Dr. Ulf Geumann, apceth Biopharma GmbH, Germany

Group Leader Preclinical Development

13:30 – 14:00Retroviral and lentiviral production: development and scaling up of upstream and downstream process steps

Dr. Francesca Bellintani, MolMed, Italy

Vector Downstream Process Development Manager

14:00 – 14:10Sum up & Closing

Speaker Line-Up

Keynote Lecture by the Winner and Lectures by the 3 Finalists of "The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy 2018"

Dr. Priscilla N. Kelly,
Washington DC, USA

AAAS/Science

Editor for biomedicine

Topic: "How to publish in Science"

©*

Prof. Dr. Stefan W. Hell,
Goettingen, Germany

Max Planck Institute for Biophysical Chemistry

Managing Director Max Planck Institute for Biophysical Chemistry

Nobel laureate of 2014 in chemistry 

*© Peter Badge/Typos1 in cop. with Foundation Lindau Nobel Laureate Meetings
all rights reserved 2017.

Dr. Ulf Geumann,
Munich, Germany

apceth Biopharma GmbH
Group leader Preclinical Development

Topic: Mesenchymal stem cells in immunotherapy

Overview: apceth is harnessing the potential of mesenchymal stem cells (MSC), in which the mechanism of therapeutic effects are very different from that of CAR-T cells. The aim is to provide innovative cell-based gene therapies for the treatment of major indications such as cancer, chronic lung and kidney diseases and for immunomodulation. 

apceth has created its allogenic therapeutic platform based entirely on the genetic engineering of MSC isolated from healthy donors. 

Francesca Bellintani,
Milan, Italy

MolMed
Vector Downstream Process Development Manager

Topic: Retroviral and lentiviral production: development and scaling up of upstream and downstream process steps

Overview: MolMed has implemented a large-scale process to meet the increasing demand for clinical and commercial grade vector production. There is a special focus on identification of challenges in the downstream/purification strategy to ensure efficient contaminant removal and preservation of viral infectivity.


Dr. Thierry Wurch,
Suresnes, France

Servier
Director of External Studies in Immuno-oncology

Topic: Allogenic approach developed by Servier and the preclinical data of UCART19

Overview: Servier is applying the Cellectis’ TALEN gene editing technology to overcome current limitations and provide an allogeneic, frozen, “off-the-shelf” T cell based medicinal product.

UCART19 is an allogeneic CAR T-cell product candidate being developed for treatment of CD19-expressing hematological malignancies. It is currently being evaluated in a phase 1 clinical trials in relapsed/refractory acute lymphoblastic leukemia (ALL) of adult and pediatric patients. The selection of UCART19 as a candidate was based on the impressive clinical benefits leading to the marketing of the two first autologous CAR T-cell products Kymriah (Novartis) and Yescarta (Kite Gilead). 

Dr. Nina G. Bauer,
Basel, Switzerland

Lonza
Assoc. Director of Commercial Development, Autologous Cell Therapies

Topic: Manufacturing strategies for patient scale cell therapies

Overview: The “Future Technologies” business area under the Pharma & Biotech division of Lonza has a focus on personalized medicine & cell therapy. One of the major challenges in these fields is the production of the patient-specific and patient-scale CAR-T cells or stem cells for treatment. 

Lonza has partnered with Octane on the Octane CocoonTM platform, which offers a ground-breaking innovation to address this challenge. Unlike current, labor-intensive production methods, this platform has the potential to enable the automated manufacturing of patient-specific cell therapies for maximum efficiency, traceability and scale-up. 

Lectures from “The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy” Winner and Finalists.


Prof. Dr. Stefan Wölfl,
Heidelberg, Germany

University of Heidelberg,
Institute for Pharmacy and molecular Biotechnology

Topic: Small molecules to enable, faciliate and improve iPSC generation and cell reprogramming

The generation of patient specific specialized cell-types is a major task in regenerative medicine. Despite the success of genetic reprogramming protocols, it is still a challenge to generate, cultivate and expand patient specific induced pluripotent stem cells (iPSCs). The generation of iPSCs requires the expression of specific transcription factors, expression of which is maintained to conserve the pluripotent state. For reprogramming these factors are inhibited and tissue specific sets of gene expression are induced. We focus on the development of chemical compounds to replace genetic reprogramming and e.g. have identified Oct4 inducing small molecules. Although we cannot yet fully replace genetic reprogramming factors, our small molecules improve reprogramming efficiency, overcome reprogramming resistance and improve cultivation of iPSCs for reprogramming.  

How to Get There

Conference address

Sartorius College
Otto-Brenner-Str. 20
37079 Goettingen, Germany

Phone +49-551-308-2101

On the A7 freeway (Hannover- Kassel), take the exit bound for Goettingen Nord (72). Then take the first exit to Industriegebiet (industrial zone) and afterwards, the first exit in the traffic circle. At the next light, make a left turn. Sartorius College will be on your left-hand side.

The nearest airports are Hanover, Kassel and Frankfurt in Germany. From there, you can reach Goettingen by train or car. By taxi, it will take about 10 minutes to get from the Goettingen train station to Sartorius College.

We have arranged for a limited number of accommodations under special conditions at the hotel listed below.

Park Inn by Radisson Goettingen
Kasseler Landstraße 25C
37081 Goettingen, Germany

Phone +49-551-2707070
www.parkinn.com/hotel-gottingen

top

Impressions of Research Xchange Forum 2017

Trends and Challenges in Oncology

Our first Research Xchange Forum about trends and challenges in oncology took place in February 2017. Lectures given by 12 internationally renowned academics and leading biopharma R&D executives provided insights into the latest developments of their specific cancer research and therapy approaches. At this event, we also focused exchanging ideas and enhancing collaboration between academia and industry. This also included a lively panel discussion covering controversial opinions. 

 

Get impressions: review of the 2-day Forum

top

Ticket Prices

We offer an early bird discount up to January 15, 2018.

The registration fee includes admission, gala dinner, all coffee breaks, lunches and the optional plant tour. Advance registration is required.

Industry/
Business
Academia  Postdocs/ PhD Students/
Students
Early Bird395 EUR*295 EUR*105 EUR*
Regular595 EUR*495 EUR*195 EUR*
Group TicketPay for the 1st ticket and get 50% off on every additional registration

*All prices are excluding VAT

top

Any Further Questions?

If you should have any questions, do not hesitate to contact us at any time. We would be pleased to help you.

Romi Jeromis 
Sartorius Lab Instruments GmbH & Co. KG 
Phone: +49-551-308-2659 
forum sartorius.com

top